2012
Predictors of residual disease after breast-conserving surgery.
Aneja S, Lannin D, Killelea B, Horowitz N, Chagpar A. Predictors of residual disease after breast-conserving surgery. Journal Of Clinical Oncology 2012, 30: 168-168. DOI: 10.1200/jco.2012.30.27_suppl.168.Peer-Reviewed Original ResearchResidual invasive diseaseResidual invasive cancerResidual DCISInvasive cancerInvasive diseaseResidual diseaseMargin distanceSitu diseaseTumor sizeBreast cancerRetrospective cohort studyInvasive breast cancerBreast-conserving surgerySitu breast cancerCavity shave marginsMain outcome variablesCohort of interestLocoregional failureChart reviewCohort studyLymphovascular invasionPathologic factorsAdditional resectionPostoperative managementRisk stratificationCan primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?
Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.Peer-Reviewed Original ResearchBreast cancer patientsLN statusCancer patientsLymphovascular invasionTumor sizeTumor markersPositive LNsPoor prognosisMedian numberPrimary tumor markersMedian patient ageMedian tumor sizeLymph node positivityLN-positive patientsLymph node statusOnly factorCancer initiating cellsCancer-initiating cellsLevels of CD44Axillary surgeryLN positivityNode positivityPatient agePositive patientsClinicopathologic data
2011
P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior?
Lush E, Dedert E, Daup M, Dhabhar F, Spiegel D, Tillie J, McMasters K, Sephton S, Chagpar A. P1-01-15: Do Serum Cytokines Predict Breast Cancer Behavior? Cancer Research 2011, 71: p1-01-15-p1-01-15. DOI: 10.1158/0008-5472.sabcs11-p1-01-15.Peer-Reviewed Original ResearchSerum cytokine levelsHormone receptor statusLymph node statusCytokine levelsReceptor statusTumor sizeBreast cancer behaviorSerum cytokinesNode statusCancer behaviorIFN-gamma serum levelsMedian patient ageMedian tumor sizeSerum IFN-gammaSerum inflammatory cytokinesProgesterone receptor statusRole of inflammationFinal pathologic resultsPresence of metastasesBreast cancer patientsBreast cancer developmentVariety of cytokinesCohort of interestLymphovascular invasionPatient ageFactors affecting lymphovascular invasion in node-positive breast cancer patients.
Cornwell L, McMasters K, Chagpar A. Factors affecting lymphovascular invasion in node-positive breast cancer patients. Journal Of Clinical Oncology 2011, 29: 24-24. DOI: 10.1200/jco.2011.29.27_suppl.24.Peer-Reviewed Original ResearchBreast cancer patientsLVI positivityCancer patientsExtracapsular extensionLarge tumorsNode-positive breast cancer patientsPositive lymph nodesProportion of patientsCohort of patientsPoor prognostic factorProspective multicenter studySynoptic pathology reportsBreast cancer tumorsBreast practicePositive nodesLarge metastasesLymphovascular invasionPatient agePrognostic factorsSurgery typeClinicopathologic factorsLymph nodesMulticenter studyVascular invasionPathology reportsHow Can the AJCC Staging System Be Improved?
Chagpar A. How Can the AJCC Staging System Be Improved? Current Breast Cancer Reports 2011, 3: 104-108. DOI: 10.1007/s12609-011-0041-9.Peer-Reviewed Original ResearchAJCC staging systemStaging systemCurrent American Joint CommissionTumor cellsInternal mammary nodesStage IV diseasePrimary tumor stagingCancer (AJCC) staging systemLymph node metastasisAmerican Joint CommissionBreast cancer researchMammary nodesLymphovascular invasionNode metastasisDistant metastasisTumor stagingBreast cancerOptimal stagingJoint CommissionMetastasisStagingCancer researchMicrometastasesCellsLymph
2009
Prediction of Thromboembolic Events in Women with Hormone Receptor-Positive Breast Cancer Receiving SERMS
Lewis J, Chagpar A, McMasters K, Edwards M. Prediction of Thromboembolic Events in Women with Hormone Receptor-Positive Breast Cancer Receiving SERMS. Journal Of Surgical Research 2009 DOI: 10.1016/j.jss.2009.03.089.Peer-Reviewed Original ResearchSelective estrogen receptor modulatorsHormone receptor-positive breast cancerReceptor-positive breast cancerDeep venous thrombosisThromboembolic eventsPulmonary emboliBreast cancerTamoxifen Adjuvant trialTransient ischemic attackOnly independent factorAcute myocardial infarctionEstrogen receptor modulatorsAdjuvant trialsIschemic attackPositive nodesThromboembolic riskLymphovascular invasionCerebrovascular accidentClinicopathologic factorsVenous thrombosisTreatment armsMyocardial infarctionUnivariate analysisReceptor modulatorsResults NinetyFactors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer.
Chagpar A, Lewis J, McMasters K, Edwards M. Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer. Cancer Research 2009, 69: 4105. DOI: 10.1158/0008-5472.sabcs-4105.Peer-Reviewed Original ResearchAddition of chemotherapyHormone receptor-positive breast cancerReceptor-positive breast cancerAbsolute survival benefitAdjuvant hormonal therapyOverall survival benefitHormonal therapySurvival benefitOverall survivalAdjuvant chemotherapyClinicopathologic factorsAbsolute benefitBreast cancerHormone receptor-positive patientsReceptor-positive patientsTamoxifen Adjuvant trialMedian patient ageMedian tumor sizeMajority of patientsYears of ageCohort of interestAdjuvant trialsLymphovascular invasionPatient agePositive disease